Patrick D. Yeramian - 06 Jan 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Chief Medical Officer
Signature: /s/ Joshua B. Cohen, as Attorney-in-Fact for Patrick D. Yeramian
Issuer symbol: AMLX
Transactions as of: 06 Jan 2022
Transactions value $: $0
Form type: 3
Filing time: 06 Jan 2022, 16:02:24 UTC
Next filing: 10 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AMLX	Common Stock						178K	06 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AMLX	Stock Option (Right to Buy)							06 Jan 2022	Common Stock	2.79K	$0.33	Direct	F1
holding	AMLX	Stock Option (Right to Buy)							06 Jan 2022	Common Stock	92.5K	$0.37	Direct	F2
holding	AMLX	Stock Option (Right to Buy)							06 Jan 2022	Common Stock	65K	$6.88	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As of the date of this filing, 1,673 shares subject to the option are vested and exercisable. The remaining 1,116 shares subject to such option vest and become exercisable in substantially equal installments until February 16, 2022.
F2	As of the date of this filing, 8,874 shares subject to the option are vested and exercisable. 33,013 shares subject to such option vest and become exercisable in substantially equal monthly installments until March 18, 2023, and 50,620 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
F3	16,256 shares subject to such stock option shall vest on February 19, 2022 and the remainder of the shares vest in monthly installments of 1,354 shares thereafter.